Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoromethane SCHEMBL28051653 | 0.94 | HSD17B10 (0.43) | ALDH1A1GLAMAPTPOLBGFER | |
| Chloromethane SCHEMBL28051667 | 0.94 | HSD17B10 (0.43) | ALDH1A1GLAMAPTPOLBGFER | |
| SCHEMBL11163286 | 0.88 | MAPT (0.49) | ALDH1A1MAPTPOLBGFERCACNA1B | |
| SCHEMBL3179819 | 0.79 | HSPB1 (0.56) | ALDH1A1MAPTPOLBL3MBTL1LMNA | |
| SCHEMBL11153190 | 0.77 | MAPT (0.56) | MAPTPOLBTDP1LMNA | |
| SCHEMBL925941 | 0.76 | ALDH1A1 (0.53) | ALDH1A1GLAMAPTPOLBGFER | |
| SCHEMBL7364055 | 0.73 | RAB9A (0.48) | ALDH1A1MAPTPOLBGFERCACNA1B | |
| SCHEMBL27909482 | 0.71 | ALDH1A1 (0.72) | ALDH1A1ACHEHSD17B10TDP1APP | |
| SCHEMBL22567 | 0.71 | ALDH1A1 (0.72) | ALDH1A1ACHEHSD17B10TDP1APP | |
| SCHEMBL28198 | 0.69 | CA1 (0.67) | ALDH1A1MAPTPOLBACHEHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776830-A | Full deuteration preparation method of polycyclic aromatic hydrocarbon | 宁波萃英化学技术有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-106632004-A | Pyridone derivative, and preparation method and application thereof | 山东大学 | 2017-05-10 | — | — | CN | claimed |
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | SCRIPPS RESEARCH INST (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4642777-A1 | INHIBITORS OF KIF18A AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-11-05 | — | — | EP | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4499149-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499068-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| EP-4472942-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | The Scripps Research Institute (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023147545-A9 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | PHARMASSET, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004013300-A2 | COMPOUNDS WITH THE BICYCLO[4.2.1]NONANE SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-5272170-A | Tetralones with pharmacological activity | J. URIACH & CIA., S.A. (ES) | 1993-12-21 | — | — | US | disclosed |
| US-5208246-A | Hypotensive, bronchodilator | J. URIACH & CIA. (ES) | 1993-05-04 | — | — | US | disclosed |
| EP-0489300-A2 | Tetralones with pharmacological activity | J. URIACH & CIA. S.A. (ES) | 1992-06-10 | — | — | EP | disclosed |
| EP-0147105-B1 | PHOTOGRAPHIC PRODUCTS EMPLOYING NOVEL NONDIFFUSIBLE HYDRAZONE DYE-RELEASING COMPOUNDS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4548888-A | DIFFUSION TRANSFER | EASTMAN KODAK COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0147105-A2 | Photographic products employing novel nondiffusible hydrazone dye-releasing compounds | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | CYP4B1, HAVCR2, CYP2S1 | ALDH1A1 1212/4885GLA 4126/4885MAPT 3805/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | ALDH1A1 3843/4885GLA 1859/4885MAPT 489/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885GLA 1436/4885MAPT 22/4885 |
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | PDCD1LG2, PDCD1, CD274 | ALDH1A1 177/4885GLA 1569/4885MAPT 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.